|
Dec 05, 2024
|
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
|
|
|
Nov 26, 2024
|
Nkarta to Participate in an Upcoming Investor Conference
|
|
|
Nov 12, 2024
|
Nkarta to Participate in an Upcoming Investor Conference
|
|
|
Nov 07, 2024
|
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
|
|
|
Sep 03, 2024
|
Nkarta to Participate in Upcoming Investor Conference
|
|
|
Aug 13, 2024
|
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
|
|
|
Jul 24, 2024
|
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
|
|
|
Jul 16, 2024
|
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
|
|
|
Jun 27, 2024
|
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
|
|
|
Jun 13, 2024
|
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
|
|
